Navigation Links
Aethlon Medical Releases Shareholder Letter
Date:9/15/2009

SAN DIEGO, Sept. 15 /PRNewswire-FirstCall/ -- Aethlon Medical, Inc., (OTC Bulletin Board: AEMD) disclosed today that its Chairman and CEO, James A. Joyce has issued the following letter to shareholders.

(Logo:http://www.newscom.com/cgi-bin/prnh/20090325/LA88762LOGO-b)

    To our Shareholders:

    In advance of tomorrow's annual meeting, I wish to thank those
    shareholders who returned proxies supporting measures to re-elect our
    board of directors, reappoint our auditors, and increase the authorized
    shares of our common stock.  The results of your votes will be tabulated
    during our meeting and disclosed shortly thereafter.

    I would also like to take this opportunity to disclose that our
    manufacturing program with Bioserv/NextPharma Technologies is now
    underway, and that infectious disease researchers have provided initial
    verification that our Hemopurifier(R) is able to capture the emerging H1N1
    swine flu virus. We are additionally honored to reestablish a cooperative
    research and development agreement with the U.S. Army Medical Research
    Institute of Infectious Diseases (USAMRIID) that will continue our
    research into treating Ebola and other highly lethal pathogens.

    While I am pleased we have advanced these initiatives, our primary focus
    remains directed towards leveraging our therapeutic opportunity in
    Hepatitis-C care and establishing strategic relationships that will
    maximize long-term economic value for shareholders.  In this regard, we
    are actively pursuing relationships that offer to augment or
    significantly expand our clinical, distribution, and manufacturing
    capabilities.  However, I want to stress the complexity underlying any
    such relationship should not be underestimated.  We face issues that
    include competition between players in the medical device space, scaling
    of manufacturing at feasible costs, and developing appropriate
    distribution channels in a variety of markets.  Additionally, we maintain
    a firm stance that Aethlon Medical shareholders should maintain 100%
    ownership of our Hemopurifier(R) technology.  Regardless of these
    challenges, I am increasingly confident that we will establish
    relationships that provide us the foundation to transition our science
    into a successful business enterprise.

    On behalf of our dedicated team at Aethlon Medical, I thank you for your
    continued support and look forward to meeting those of you who attend
    tomorrow's meeting.

    Very truly yours,

    James A. Joyce
    Chairman, CEO

Certain of the statements within this shareholder letter may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the Company's ability to forge corporate partnerships on terms acceptable to the Company or at all, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.

    Contacts:

    Jon Cunningham
    RedChip Companies Inc.
    (407) 644-4256
    (407) 491-4498 -cell
    Dave@redchip.com or Jon@redchip.com

    Jim Joyce
    Chairman, CEO
    858.459.7800 x301
    jj@aethlonmedical.com

    Jim Frakes
    Senior VP Finance
    858.459.7800 x300
    jfrakes@aethlonmedical.com


'/>"/>
SOURCE Aethlon Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Aethlon Medical to Present at Todays Southern California Investor Conference
2. Aethlon Medical Initiates Swine Flu Testing Program
3. Aethlon Medical Announces U.S. Army Agreement
4. Aethlon Medical Releases Shareholder Letter to Discuss the Treatment of Hepatitis-C Virus (HCV)
5. Aethlon Medical Discloses New HIV/AIDS Treatment Data
6. Aethlon Medical Confirms Hemopurifier(R) Is a Treatment Candidate Against Swine Flu Virus
7. Aethlon Medical Announces Engagement of RedChip Companies to Initiate Investor and Media Relations Programs
8. Aethlon Medical Announces CEO Interview and Corporate Presentation Available Online
9. Emergency Medical Transport By Air Carries Risks
10. Bayer and Onyx Announce Nexavar Data Presentations at the Joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress
11. Medical Doctor Creates Mantra Medicine Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... September 19, 2017 , ... Spain’s popular line ... Laboratories, is coming soon to RonnieColemanNutrition.com. , ACPG Laboratories has been in ... trusted, well-respected brand reliant on the healing properties of plants, a proven science ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... to serve as strategic adviser to the animal healthcare division of Sonoma ... Bridge Animal Referral Center (BARC) in Edmonds, Washington, which specializes in compassionate ...
(Date:9/19/2017)... ... , ... Premiere Long Island dental office Gold Coast Smiles is pleased to ... dentists in America under age 40 by Incisal Edge magazine. , Incisal Edge ... the best 40 dentists under the age of 40 renowned for medical innovations and ...
(Date:9/19/2017)... ... September 19, 2017 , ... When it comes to household ... deserve clear instructions on how to keep babies and toddlers safe, and there's no ... Safety Month. , Great Time to Check Labels, Brands that sell all kinds of ...
(Date:9/19/2017)... ... September 19, 2017 , ... Emergency ... the Certified Emergency Nurse (CEN®) certification according to a large-scale study ... of certification study, conducted by the Human Resources Research Organization (HumRRO) in late ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... TORONTO , Sept. 6, 2017 /PRNewswire/ ... new knowledge and skills while treating their ... for hands-on experience without involving patients. Simulation ... skills. Clinicians can carry out procedures, refine ... at risk. Integration of new technology, such ...
(Date:9/5/2017)... KEYSTONE, Colo. , Sept. 5, 2017 ... their XR-29 DoseCheck solution. Scannerside DoseCheck is a third-party ... update existing CT scanners and allows compliance with current ... The Sapheneia-Scannerside proprietary XR 29 DoseCheck solution is specifically ... notifications and alerts of potential radiation doses over a ...
(Date:9/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ... company focused on the development of oral drug delivery ... meeting with the U.S. Food and Drug Administration (FDA) ... At the meeting, the ... submission of ORMD-0801, would be a Biologics License Application ...
Breaking Medicine Technology: